Évaluation monocentrique de la tolérance de l’association concomitante de trastuzumab et de radiothérapie

Alm En-Din, 2008, Radiation treatments may contribute to the development of cardiac dysfunction in breast cancer patients treated with chemotherapy and trastuzumab, Int J Radiat Oncol Biol Phys, 72, S89, 10.1016/j.ijrobp.2008.06.970 Belkacemi, 2008, Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: Acute toxicity analyses from the French multicentric study, Ann Oncol, 19, 1110, 10.1093/annonc/mdn029 Belkacemi, 2007, Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer, Cancer Radiother, 11, 266 Bellon, 2005, Concurrent Trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer, Int J Radiat Oncol Biol Phys, 63, S55, 10.1016/j.ijrobp.2005.07.097 Bollet, 2006, Breast radiotherapy in women with pectus excavatum (funnel chest): Is the lateral decubitus technique an answer? A dosimetric study, Br J Radiol, 79, 785, 10.1259/bjr/23839243 Campana, 2005, Breast radiotherapy in the lateral decubitus position: A technique to prevent lung and heart irradiation, Int J Radiat Oncol Biol Phys, 61, 1348, 10.1016/j.ijrobp.2004.08.051 Castro Pena P, Kirova Y, Campana F, Dendale R, Bollet MA, Fournier-Bidoz N, et al. Anatomical, Clinical and radiological delineation of target volumes in breast cancer radiotherapy planning: individual variability, questions and answers. Br J Radiol 2009:doi:10.1259/bjr/96865511. Chargari C, Fromantin I, Kirova Y. Intérêt des applications cutanées en cours de radiothérapie pour la prévention et le traitement des épithélites radio-induites. Cancer Radiother 2009:doi:10.1016/j.canrad.2009.04.003. Couturier, 2008, Diagnosis of HER2 gene amplification in breast carcinoma, Pathol Biol (Paris), 56, 375, 10.1016/j.patbio.2008.03.009 Elston, 1991, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up, Histopathology, 19, 403, 10.1111/j.1365-2559.1991.tb00229.x Ewer, 2005, Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment, J Clin Oncol, 23, 7820, 10.1200/JCO.2005.13.300 Halyard, 2006, Adjuvant radiotherapy (RT) and trastuzumab in stage I-IIA breast cancer: Toxicity data from North Central Cancer Treatment Group Phase III trial N9831, J Clin Oncol (Meeting Abstracts), 24, 523, 10.1200/jco.2006.24.18_suppl.523 Hennequin, 2008, Irradiation of lymph nodes areas in breast cancer, Cancer Radiother, 12, 559, 10.1016/j.canrad.2008.07.016 Hurkmans, 2000, Cardiac and lung complication probabilities after breast cancer irradiation, Radiother Oncol, 55, 145, 10.1016/S0167-8140(00)00152-3 Joensuu, 2006, Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer, N Engl J Med, 354, 809, 10.1056/NEJMoa053028 Kirova, 2007, Postmastectomy electron beam chest wall irradiation in women with breast cancer: A clinical step toward conformal electron therapy, Int J Radiat Oncol Biol Phys, 69, 1139, 10.1016/j.ijrobp.2007.05.007 Kirova, 2008, How to boost the breast tumor bed? A Multidisciplinary Approach in eight steps, Int J Radiat Oncol Biol Phys, 72, 494, 10.1016/j.ijrobp.2007.12.059 Kirova, 2006, CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning, Radiother Oncol, 79, 310, 10.1016/j.radonc.2006.05.014 Kong, 2002, The impact of central lung distance, maximal heart distance, and radiation technique on the volumetric dose of the lung and heart for intact breast radiation, Int J Radiat Oncol Biol Phys, 54, 963, 10.1016/S0360-3016(02)03741-0 Musat, 2007, Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes, Eur J Cancer, 43, 718, 10.1016/j.ejca.2006.11.015 Pietras, 1999, Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene, Cancer Res, 59, 1347 Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 Slamon, 1987, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Smith, 2007, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial, Lancet, 369, 29, 10.1016/S0140-6736(07)60028-2